The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease.

OBJECTIVE AND DESIGN high plasma levels of Interleukin-6 (IL-6) are found in patients with atherosclerotic disorders. Recently, a common polymorphism of the IL-6 gene promoter, influencing the transcription rate of the gene, has been described and associated with atherosclerosis of carotid and coronary arteries. The objective of this study was to test whether IL-6 gene promoter polymorphism is associated with peripheral artery occlusive disease (PAOD) in a case-control study. METHODS IL-6 gene promoter polymorphism was evaluated by polymerase chain reaction followed by restriction enzyme analysis in 84 patients affected by PAOD and 183 controls. RESULTS the distribution of IL-6 genotypes was: patients with PAOD: 44 GG, 30 GC, 10 CC; control subjects: 53 GG, 80 GC, 50 CC. The GG genotype was significantly more common in the PAOD group (p<0.0001), while the CC genotype was significantly more common in control patients (p=0.005). CONCLUSIONS this study indicates a strong association between IL-6 gene polymorphism and PAOD and support the hypothesis that IL-6 and IL-6 gene polymorphism are important in the pathophysiology and evolution of ischaemic diseases of the lower limbs.

[1]  E. Hawe,et al.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. , 2001, European heart journal.

[2]  A. Grau,et al.  Increased cytokine release by leucocytes in survivors of stroke at young age , 2001, European journal of clinical investigation.

[3]  J. Powell,et al.  Interleukin-6 (IL-6) and the Prognosis of Abdominal Aortic Aneurysms , 2001, Circulation.

[4]  A. Marian.  On genetics, inflammation, and abdominal aortic aneurysm: can single nucleotide polymorphisms predict the outcome? , 2001, Circulation.

[5]  C. Bouchard,et al.  Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[6]  F. Green,et al.  Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.

[7]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[8]  F. Jessen,et al.  Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population , 2000, Neuroscience Letters.

[9]  P. Nihoyannopoulos,et al.  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. , 1999, Circulation.

[10]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[11]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[12]  M. Halks-Miller,et al.  Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[13]  R. Ross,et al.  Atherosclerosis is an Inflammatory Disease , 1998 .

[14]  D. Papanicolaou,et al.  The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.

[15]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[16]  H. Rus,et al.  Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. , 1996, Atherosclerosis.

[17]  G. Ciliberto,et al.  Elevated levels of interleukin-6 in unstable angina. , 1996, Circulation.

[18]  J. Parodi,et al.  Carotid atherosclerosis. Immunocytochemical analysis of the vascular and cellular composition in endarterectomies. , 1996, Cardiologia.

[19]  T. Sakamoto,et al.  Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. , 1993, American heart journal.

[20]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[21]  G. Courtois,et al.  The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element , 1993, Molecular and cellular biology.

[22]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[23]  R. Rutherford,et al.  Suggested standards for reports dealing with lower extremity ischemia. Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. , 1986, Journal of vascular surgery.

[24]  V. Fuster,et al.  Atherosclerosis and coronary artery diseases , 1996 .

[25]  J. Willerson,et al.  Role of inflammation in coronary plaque disruption. , 1994, Circulation.

[26]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[27]  J. Snick,et al.  Interleukin-6: an overview. , 1990, Annual review of immunology.